

Alzheimer's Disease - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A1C4172E08CEN.html>

Date: August 2020

Pages: 1785

Price: US\$ 2,500.00 (Single User License)

ID: A1C4172E08CEN

Abstracts

Alzheimer's Disease - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H2 2020, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development

by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 21, 61, 77, 1, 4, 345, 134 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 2, 100 and 47 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Alzheimer's Disease - Overview

Alzheimer's Disease - Therapeutics Development

Alzheimer's Disease - Therapeutics Assessment

Alzheimer's Disease - Companies Involved in Therapeutics Development

Alzheimer's Disease - Drug Profiles

Alzheimer's Disease - Dormant Projects

Alzheimer's Disease - Discontinued Products

Alzheimer's Disease - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Alzheimer's Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Number of Products by Stage and Molecule Type, H2 2020 (Contd..1), H2 2020
Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, H2 2020
Alzheimer's Disease - Pipeline by 2A Pharma AB, H2 2020
Alzheimer's Disease - Pipeline by 4P-Pharma SAS, H2 2020
Alzheimer's Disease - Pipeline by AB Science SA, H2 2020
Alzheimer's Disease - Pipeline by Abaxy Sprl, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Alzheimer's Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

1st Bio Therapeutics Inc
2A Pharma AB
4P-Pharma SAS
AB Science SA
Abaxy Sprl
AbbVie Inc
AC Immune SA
Acadia Pharmaceuticals Inc
Accutis Pharmaceuticals Inc
Acelerox LLC
Acelot Inc
Actinogen Medical Ltd
Acumen Pharmaceuticals Inc
Addex Therapeutics Ltd
Adocia SAS
ADRx Inc
Aerobyx LLC
AfaSci Inc
Affichem SA
Aibios Co Ltd
Alector Inc

Alfasigma SpA
Alkahest Inc
Alkermes Plc
AlphaCognition Inc
Alsonex Pty Ltd
ALSP Inc
Alzamend Neuro Inc
AlzeCure Pharma AB
Alzheon Inc
Alzhyme Pty Ltd
Alzinova AB
AlzProtect SAS
Alzyn LLC
Amyloid Solution Inc
Amylon LLC
Amylyx Pharmaceutical Corp
Anavex Life Sciences Corp
Ankar Pharma SL
Annovis Bio Inc
Antoxerene Inc
Anven AlzDx Inc
Aphios Corp
Apodemus AB
Apollo Therapeutics LLC
Applied Research using OMIC Sciences SL
Aprinoia Therapeutics Inc
AptaBio Therapeutics Inc
Araclon Biotech SL
Archer Pharmaceuticals Inc
AriBio
ArmaGen Inc
Armgo Pharma Inc
Artery Therapeutics Inc
Arvinas Inc
Asceneuron SA
Asdera LLC
AskAt Inc
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc

AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
AstronauTx Ltd
Athira Pharma Inc
ATP Biopharm
Augustus BioTarget Inc
Auransa Inc
Aurin Biotech Inc
Auritec Pharmaceuticals Inc
Autifony Therapeutics Ltd
Autophagy Neurotherapeutics Inc
Avanti Biosciences Inc
Avidin Biotechnology Ltd
Avineuro Pharmaceuticals Inc
Axon Neuroscience SE
Axxam SpA
AZTherapies Inc
BCWorld Pharm Co Ltd
Benuvia Therapeutics Inc
Berg LLC
BeyondBio Inc
Bio-Pharm Solutions Co Ltd
BioArctic AB
Biogen Inc

I would like to order

Product name: Alzheimer's Disease - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A1C4172E08CEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1C4172E08CEN.html>